Clean Cells, part of the Clean Biologics group, a provider of biopharmaceutical product quality control services and manufacturer of starting materials, is investing $15.3 million for a new production facility in Montaigu‑Vendée, France. By quadrupling its analysis and production capacity for biopharmaceuticals, the group intends to play a key role in speeding up the development and time-to-market of novel treatments and vaccines for COVID‑19.   Clean Cells’ new laboratories, with a footprint of...